Table 2. Treatment-Related Adverse Events by Treatment Arm^a.

Adverse events	Armc	No. (%)b
		Grade 2	Grade 3	Grade 4
Neutrophil count decreased	1	7 (15)	11 (24)	8 (17)
	2	6 (13)	9 (20)	10 (22)
White blood cell decreased	1	13 (28)	6 (13)	2 (4)
	2	8 (18)	10 (22)	4 (9)
Alopecia	1	19 (41)	0	0
	2	18 (40)	0	0
Anemia	1	10 (22)	7 (15)	1 (2)
	2	10 (22)	4 (9)	0
Fatigue	1	11 (24)	0	0
	2	13 (29)	4 (9)	0
Lymphocyte count decreased	1	5 (11)	2 (4)	0
	2	5 (11)	6 (13)	0
Anorexia	1	7 (15)	0	0
	2	3 (7)	1 (2)	0
Platelet count decreased	1	2 (4)	2 (4)	1 (2)
	2	2 (4)	1 (2)	1 (2)
Mucositis oral	1	4 (9)	1 (2)	0
	2	1 (2)	1 (2)	0
Nausea	1	1 (2)	0	0
	2	3 (7)	1 (2)	0
Febrile neutropenia	1	0	1 (2)	0
	2	0	1 (2)	1 (2)
Thromboembolic event	1	0	0	0
	2	0	3 (7)	0
Acute coronary syndrome	1	0	0	1 (2)
	2	0	0	0
Investigations: thrombotic microangiopathic hemolysis	1	0	0	1 (2)
	2	0	0	0

^a One grade 5 respiratory failure that was at least possibly related to treatment occurred in arm 2.

^b All grade 3 to 4 adverse events at least possibly related to treatment and the most common grade 2 adverse events (>10% in at least 1 treatment arm) at least possibly related to treatment were included.

^c Arm 1 alisertib monotherapy and arm 2 alisertib + fulvestrant.